The Hormones and Cancer research group is a consolidated group of the IMIBIC comprised by basic, translational, and clinical researchers. We investigate the cellular and molecular principles underlying the natural processes of neuroendocrine-metabolic regulation and their dysfunctions in tumors and cancer. The group pays special attention to the role played by certain neuropeptide/receptor systems and their regulation by distinct mechanisms, especially alternative splicing and its related RNA controlling processes and associated signalling pathways, at the onco-endocrine interface. The original focus of our group laid on the study of pituitary cell biology, particularly growth hormone (GH)-producing somatotropes and their regulatory signals (somatostatin, cortistatin, GHRH, ghrelin, Kisspeptins, etc.) and receptors (SST1-5, GHRHR, GHSR1, KISS1R), and signalling pathways. This line evolved to study pituitary neuroendocrine tumors (PitNETs) and expanded definitely with the discovery of novel, abnormal splicing variants (SST5TMD4, In1-ghrelin) and the study of their pathophysiological role in somatotropes and other endocrine cell types (eg. corticotropes, gonadotropes, pancreatic beta cells) and, broadly, in tumor development and metabolic dysfunction. Currently, our work is centred in the pathophysiology of neuroendocrine tumors (NETs) from pancreatic, gastrointestinal and lung origin, and of pancreatic ductal adenocarcinoma (PDAC), wherein we investigate the actions of diverse molecular regulatory systems (including somatostatin, ghrelin, etc.) and the specific role of alternative splicing and RNA biology.
To achieve our goals, we use a wide range of techniques, including primary cultures of normal and tumor cells, cell lines, genetically modified animals, measurements of peptides, hormones, second messengers and gene expression of diverse molecular components, particularly of the spliceosome machinery, as well as dynamic imaging of molecular trafficking, confocal microscopy in living cells, etc. We are developing and applying biocomputational approaches to explore the spliceosomic landscape in different experimental and clinical settings with the aim of further understanding the contribution of splicing and RNA metabolism to cancer and other diseases.
Our studies have led to the discovery and characterization of new receptors, splicing variants, functions and mechanisms of action for different neuroendocrine-metabolic signals and drugs controlling hormone secretion, tumorigenesis or cell death and survival in normal and pathological conditions, such as metabolic dysregulations (diabetes, obesity) and cancer (PitNETs, NETs, pancreatic cancer, and breast, prostate, and liver cancers, among others). Our ultimate aim is to contribute to the discovery of novel biomarkers for early detection, improved diagnosis and predictive prognosis of the tumors studied, as well as to identify actionable targets for the design of innovative personalized therapeutic strategies, which would jointly enable the advancement of precision medicine in NETs and pancreatic cancer.
Lines of Research
Studies currently in progress in this field focus on the study of the dysregulation of the splicing machinery in neuroendocrine tumours from different locations, mainly pancreas, lung, gastrointestinal tract and hypophysis. In These tumour pathologies have shown the existence of characteristic splicing variants and preliminary studies indicate that there is a dysregulation in the machinery responsible for splicing, the spliceosome. The translational approach of these studies are also intended to assess the effect of current and new therapies for the treatment of neuroendocrine tumours on the genesis of new variants of alternative splicing, and the deregulation of alternative splicing variants, and the deregulation of the splicing machinery.
- Identify the role of alternative splicing (components of the spliceosome, splicing factors and splicing variants) in the development and progression of neuroendocrine tumours and their response to treatment.
- To explore the usefulness of its elements as potential new biomarkers for diagnosis, prognostic prediction, or targets for tumour treatment.
A second line of research focuses on the search for new diagnostic, prognostic and therapeutic biomarkers for pancreatic cancer. To achieve these objectives, we have worked on a multidisciplinary strategy that includes: clinical, histopathological and molecular characterisation ofclinical, histopathological and molecular characterisation of pancreatic ductal adenocarcinoma from both retrospective and prospective perspectives.
The use of preclinical models of tumour development, and the use of primary crops and model cell lines, will help characterise the association and involvement of the alternative splicing system in this devastating pathology.
- Characterisation of the involvement of the splicing-related molecular events and elements: alterations in spliceosome components, splicing factors and splicing variants, in the initiation, development and progression of pancreatic cancer.
- To explore the possibility of using spliceosome components, splicing factors and/or splicing variants as molecular targets for the treatment of pancreatic cancer.
- To identify biomarkers for the early diagnosis of pancreatic cancer using minimally invasive samples.
Networks
CIBERobn - Physiopathology of Obesity and Nutrition
GETNE - Spanish Group of Neuroendocrine Tumours – Spanish Society of Medical Oncology
TransBioNet – Spanish Bioinformatics Network for Clinical Research
SEEN - Area of Knowledge of Neuroendocrinology - Spanish Society of Endocrinology and Nutrition
SAEDYN - Neuroendocrinology Work Group - Andalusian Society of Endocrinology, Diabetes and Nutrition
ceiA3 - Agrifood Campus of International Excellence
ENETS - European Neuroendocrine Tumor Society - Advisory Board and Educational and Lung NET task forces
ESE - European Society of Endocrinology - Pituitary and Neuroendocrinology Focus Area.
REMAH - Spanish Molecular Registry of Hypophyseal Adenomas
PAIDI BIO-139 Cellular and molecular endocrinology (Andalusian Plan for Research, Development and Innovation - PAIDI)
Key Words
- cellular and molecular endocrine oncology
- pancreatic cancer
- neuroendocrine tumors
- pituitary tumors
- alternative splicing
- splice-variants
- spliceosome
- somatostatin
- somatostatin-receptors
- cortistatin
- ghrelin
- signaling
Información Adicional
Publications 2024
Alors-Pérez E, Blázquez-Encinas R, Moreno-Montilla MT, García-Vioque V, Jiménez-Vacas JM, Mafficini A, González-Borja I, Luchini C, Sánchez-Hidalgo JM, Sánchez-Frías ME, Pedraza-Arevalo S, Romero-Ruiz A, Lawlor RT, Viúdez A, Gahete MD, Scarpa A, Arjona-Sánchez A, Luque RM, Ibáñez-Costa A, Castaño JP. Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. MOLECULAR ONCOLOGY. 2024. 2524-2540. DOI: 10.1002/1878-0261.13658. IF: 5 Q1 D3
Sanjuan-Sanjuan A, Alors-Perez E, Sanchez-Frías M, Monserrat-Barbudo JA, Uceda MF, Heredero-Jung S, Luque RM. Splicing Machinery Is Impaired in Oral Squamous Cell Carcinomas and Linked to Key Pathophysiological Features. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024. DOI: 10.3390/ijms25136929. IF: 4,9 Q1 D3
Montero-Hidalgo AJ, Jiménez-Vacas JM, Gómez-Gómez E, Porcel-Pastrana F, Sáez-Martinez P, Pérez-Gómez JM, Fuentes-Fayos AC, Blázquez-Encinas R, Sánchez-Sánchez R, González-Serrano T, Castro E, López-Soto PJ, Carrasco-Valiente J, Sarmento-Cabral A, Martinez-Fuentes AJ, Eyras E, Castaño JP, Sharp A, Olmos D, Gahete MD, Luque RM. SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer. SCIENCE ADVANCES. 2024. DOI: 10.1126/sciadv.ado8231. IF: 11,7 Q1 D1
Dean A, Estévez O, Centella C, Sanjuan-Sanjuan A, Sánchez-Frías ME, Alamillos FJ. Surgical Navigation and CAD-CAM-Designed PEEK Prosthesis for the Surgical Treatment of Facial Intraosseous Vascular Anomalies. JOURNAL OF CLINICAL MEDICINE. 2024. DOI: 10.3390/jcm13164602. IF: 3 Q1 D2
Blázquez-Encinas R, Alors-Pérez E, Moreno-Montilla MT, García-Vioque V, Sánchez-Frias ME, Mafficini A, López-Cánovas JL, Bousquet C, Gahete MD, Lawlor RT, Luque RM, Scarpa A, Arjona-Sánchez A, Pedraza-Arevalo S, Ibáñez-Costa A, Castaño JP. The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. CANCER GENE THERAPY. 2024. 1646-1657. DOI: 10.1038/s41417-024-00814-3. IF: 4,8 Q1 D2
Hermán-Sánchez N, G-García ME, Jiménez-Vacas JM, Yubero-Serrano EM, López-Sánchez LM, Romero-Martín S, Raya-Povedano JL, Alvarez-Benito M, Castaño JP, Luque RM, Gahete MD. The splicing machinery is dysregulated and represents a therapeutic vulnerability in breast cancer. CELLULAR AND MOLECULAR LIFE SCIENCES. 2024. DOI: 10.1007/s00018-024-05515-6. IF: 6,2 Q1 D2
Ho KKY, Fleseriu M, Wass J, Katznelson L, Raverot G, Little AS, Castano JP, Reincke M, Lopes MB, Kaiser UB, Chanson P, Gadelha M, Melmed S. A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis. LANCET DIABETES & ENDOCRINOLOGY. 2024. 209-214. DOI: 10.1016/S2213-8587(23)00382-0. IF: 44 Q1 D1
Alors-Pérez E, Pedraza-Arevalo S, Blázquez-Encinas R, García-Vioque V, Agraz-Doblas A, Yubero-Serrano EM, Sánchez-Frías ME, Serrano-Blanch R, Gálvez-Moreno MA, Gracia-Navarro F, Gahete MD, Arjona-Sánchez A, Luque RM, Ibáñez-Costa A, Castaño JP. Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response. MOLECULAR THERAPY NUCLEIC ACIDS. 2024. DOI: 10.1016/j.omtn.2023.102090. IF: 6,5 Q1 D2
Romero-Ruiz A, Granados-Rodríguez M, Bura FI, Valenzuela-Molina F, Rufián-Andújar B, Martínez-López A, Rodríguez-Ortiz L, Ortega-Salas R, Torres-Martínez M, Moreno-Serrano A, Castaño J, Michán C, Alhama J, Vázquez-Borrego MC, Arjona-Sánchez A. Breaking the Mucin Barrier: A New Affinity Chromatography-Mass Spectrometry Approach to Unveil Potential Cell Markers and Pathways Altered in Pseudomyxoma Peritonei. BIOLOGICAL PROCEDURES ONLINE. 2024. DOI: 10.1186/s12575-024-00239-0. IF: 3,7 Q1 D3
Koumarianou A, Filosso PL, Bodei L, Castano JP, Fernandez-Cuesta L, Deroose CM, Foll M, Dromain C, Reed NS, Caplin M, Capdevila J, Falkerby J, Faggiano A, Frilling A, Grande E, Hicks RJ, Kasajima A, Kos-Kudla B, Krishna BA, Lim E, Rinke A, Singh S, Thirlwell C, Volante M, Walter T. Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force. JOURNAL OF NEUROENDOCRINOLOGY. 2024. DOI: 10.1111/jne.13412. IF: 3,3 Q2 D4
Blanco-Acevedo C, Aguera-Morales E, Fuentes-Fayos AC, Pelaez-Viña N, Diaz-Pernalete R, Infante-Santos N, Muñoz-Jurado A, Porras-Pantojo MF, Ibáñez-Costa A, Luque RM, Solivera-Vela J. Decompressive Hemicraniectomy without Evacuation of Acute Intraparenchymal Hemorrhage. BIOMEDICINES. 2024. DOI: 10.3390/biomedicines12081666. IF: 3,9 Q2 D4
Zamora-Olaya JM, Tejero-Jurado R, Alañón-Martínez PE, Prieto-Torre M, Rodríguez-Medina C, Montero JL, Sánchez-Frías M, Briceño J, Ciria R, Barrera P, Poyato A, de la Mata M, Rodríguez-Perálvarez ML. Donor Atheromatous Disease is a Risk Factor for Hepatic Artery Thrombosis After Liver Transplantation. CLINICAL TRANSPLANTATION. 2024. DOI: 10.1111/ctr.15405. IF: 1,9 Q2 D5
Hernandez S, Conde E, Molero A, Suarez-Gauthier A, Martinez R, Alonso M, Plaza C, Camacho C, Chantada D, Juaneda-Magdalena L, Garcia-Toro E, Saiz-Lopez P, Rojo F, Abad M, Boni V, del Carmen S, Regojo RM, Sanchez-Frias ME, Teixido C, Paz-Ares L, Lopez-Rios F. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. 2024. 318-326. DOI: 10.5858/arpa.2022-0443-OA. IF: 3,7 Q1 D2
Cozzi A, Di Leo G, Houssami N, Gilbert FJ, Helbich TH, Benito MA, Balleyguier C, Bazzocchi M, Bult P, Calabrese M, Herrero JC, Cartia F, Cassano E, Clauser P, Docema MFD, Depretto C, Dominelli V, Forrai G, Girometti R, Harms SE, Hilborne S, Ienzi R, Lobbes MBI, Losio C, Mann RM, Montemezzi S, Obdeijn IM, Ozcan UA, Pediconi F, Pinker K, Preibsch H, Povedano JLR, Saccarelli CR, Sacchetto D, Scaperrotta GP, Schlooz M, Szabó BK, Taylor DB, Ulus SÖ, Van Goethem M, Veltman J, Weigel S, Wenkel E, Zuiani C, Sardanelli F. Preoperative breast MRI positively impacts surgical outcomes of needle biopsy-diagnosed pure DCIS: a patient-matched analysis from the MIPA study. EUROPEAN RADIOLOGY. 2024. 3970-3980. DOI: 10.1007/s00330-023-10409-5. IF: 4,7 Q1 D2
Mateos IC, de Lucas MDG, Doulatram-Gamgaram VK, Moreno-Moreno P, Jimenez-Millan AI, Botana-López M, Merino-Torres JF, Soto-Gónzalez A, Fernández-García JC, Morales-Portillo C. Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study). NUTRIENTS. 2024. DOI: 10.3390/nu16152545. IF: 4,8 Q1 D2
Lencioni G, Gregori A, Toledo B, Rebelo R, Immordino B, Amrutkar M, Xavier CPR, Kocijancic A, Pandey DP, Perán M, Castaño JP, Walsh N, Giovannetti E. Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems. SEMINARS IN CANCER BIOLOGY. 2024. 217-233. DOI: 10.1016/j.semcancer.2024.09.002. IF: 12,1 Q1 D1
Ambrosini V, Caplin M, Castano JP, Christ E, Denecke T, Deroose CM, Dromain C, Falconi M, Grozinsky-Glasberg S, Hicks RJ, Hofland J, Kjaer A, Knigge UP, Kos-Kudla B, Koumarianou A, Krishna B, Lamarca A, Pavel M, Reed NS, Scarpa A, Srirajaskanthan R, Sundin A, Toumpanakis C, Prasad V. Use and perceived utility of [18F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022. JOURNAL OF NEUROENDOCRINOLOGY. 2024. DOI: 10.1111/jne.13359. IF: 3,3 Q2 D4
Publications 2023
Espejo-Cruz ML, Gonzalez-Rubio S, Espejo JJ, Zamora-Olaya JM, Alejandre-Altamirano RM, Prieto-Torre M, Linares CI, Guerrero-Misas M, Barrera-Baena P, Poyato-Gonzalez A, Sanchez-Frias M, Ayllon MD, Rodriguez-Peralvarez ML, de la Mata M, Ferrin G. Enumeration and Characterization of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023. DOI: 10.3390/ijms24032558. IF: 5,6 Q1 D3
Blázquez-Encinas R, García-Vioque V, Caro-Cuenca T, Moreno-Montilla MT, Mangili F, Alors-Pérez E, Ventura S, Herrera-Martínez AD, Moreno-Casado P, Calzado MA, Salvatierra A, Gálvez-Moreno MA, Fernandez-Cuesta L, Foll M, Luque RM, Alcala N, Pedraza-Arevalo S, Ibáñez-Costa A, Castaño JP. Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery. JOURNAL OF TRANSLATIONAL MEDICINE. 2023. DOI: 10.1186/s12967-023-04754-8. IF: 7,4 Q1 D3
Zamora-Olaya JM, Aparicio-Serrano A, Torres VA, González AP, Montero JL, Baena PB, Frias MS, Bru RC, Delgado JB, De la Mata M, Rodríguez-Perálvarez M. Changes in the Liver Transplant Waiting List after Expanding to the 'Up-to-Seven' Criteria for Hepatocellular Carcinoma. JOURNAL OF PERSONALIZED MEDICINE. 2023. DOI: 10.3390/jpm13121670. IF: 3,4 Q2 D4
Arjona-Sanchez A, Martinez-López A, Moreno-Montilla MT, Mulsow J, Lozano-Lominchar P, Martínez-Torres B, Rau B, Canbay E, Sommariva A, Milione M, Deraco M, Sgarbura O, Torgunrud A, Kepenekian V, Carr NJ, Hoorens A, Delhorme JB, Wernert R, Goere D, Martin-Roman L, Cosyns S, Flatmark K, Davidson B, Khellaf L, Pereira-Perez F, Rodriguez-Ortiz L, Ibáñez-Costa A, Romero-Ruiz A. External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification. EJSO. 2023. 1481-1488. DOI: 10.1016/j.ejso.2023.03.206. IF: 3,8 Q1 D2
Verdú-Soriano J, Casado-Díaz A, de Cristino-Espinar M, Luna-Morales S, Dios-Guerra C, Moreno-Moreno P, Dorado G, Quesada-Gómez JM, Rodríguez-Mañas L, Lázaro-Martínez JL. Hard-to-Heal Wound Healing: Superiority of Hydrogel EHO-85 (Containing <i>Olea europaea</i> Leaf Extract) vs. a Standard Hydrogel. A Randomized Controlled Trial. GELS. 2023. DOI: 10.3390/gels9120962. IF: 4,6 Q1 D3
Fuentes-Fayos AC, G-Garcia ME, Perez-Gomez JM, Montero-Hidalgo AJ, Martin-Colom J, Doval-Rosa C, Blanco-Acevedo C, Torres E, Toledano-Delgado A, Sanchez-Sanchez R, Peralbo-Santaella E, Ortega-Salas RM, Jimenez-Vacas JM, Tena-Sempere M, Lopez M, Castano JP, Gahete MD, Solivera J, Luque RM. Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence. EBIOMEDICINE. 2023. DOI: 10.1016/j.ebiom.2023.104484. IF: 11,1 Q1 D1
Torrecillas-Baena B, Camacho-Cardenosa M, Quesada-Gomez JM, Moreno-Moreno P, Dorado G, Galvez-Moreno MA, Casado-Diaz A. Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation. JOURNAL OF CLINICAL MEDICINE. 2023. DOI: 10.3390/jcm12144632. IF: 3,9 Q2 D4
Lopez-Canovas JL, Herman-Sanchez N, del Rio-Moreno M, Fuentes-Fayos AC, Lara-Lopez A, Sanchez-Frias ME, Amado V, Ciria R, Briceno J, de la Mata M, Castano JP, Rodriguez-Peralvarez M, Luque RM, Gahete MD. PRPF8 increases the aggressiveness of hepatocellular carcinoma by regulating FAK/AKT pathway via fibronectin 1 splicing. EXPERIMENTAL AND MOLECULAR MEDICINE. 2023. 132-142. DOI: 10.1038/s12276-022-00917-7. IF: 12,8 Q1 D1
Pedraza-Arevalo S, Alors-Perez E, Blazquez-Encinas R, Herrera-Martinez AD, Jimenz-Vacas JM, Fuentes-Fayos AC, Reyes O, Ventura S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Galvez-Moreno MA, Gahete MD, Ibanez-Costa A, Luque RM, Castano JP. Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors. TRANSLATIONAL RESEARCH. 2023. 63-73. DOI: 10.1016/j.trsl.2022.07.005. IF: 7,8 Q1 D2
Alors-Pérez E, Pedraza-Arevalo S, Blázquez-Encinas R, Moreno-Montilla MT, García-Vioque V, Berbel I, Luque RM, Sainz B Jr, Ibañez-Costa A, Castaño JP. Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2023. DOI: 10.1186/s13046-023-02858-z. IF: 11,3 Q1 D2
Lopez-Pedrera C, Patino-Trives AM, Cerdo T, Ortega-Castro R, Sanchez-Pareja I, Ibanez-Costa A, Munoz-Barrera L, Abalos-Aguilera MC, Ruiz-Vilchez D, Azpilcueta PS, Espinosa M, Barbarroja N, Escudero-Contreras A, Castano JP, Luque R, Ortega R, Aguirre MA, Perez-Sanchez C. Splicing machinery is profoundly altered in systemic lupus erythematosus and antiphospholipid syndrome and directly linked to key clinical features. JOURNAL OF AUTOIMMUNITY. 2023. DOI: 10.1016/j.jaut.2022.102990. IF: 12,8 Q1 D1
Lopez-Pedrera C, Oteros R, Ibáñez-Costa A, Luque-Tévar M, Muñoz-Barrera L, Barbarroja N, Chicano-Gálvez E, Marta-Enguita J, Orbe J, Velasco F, Perez-Sanchez C. The thrombus proteome in stroke reveals a key role of the innate immune system and new insights associated with its etiology, severity, and prognosis. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2023. 2894-2907. DOI: 10.1016/j.jtha.2023.04.015. IF: 10,4 Q1 D1
Jimenez-Vacas JM, Montero-Hidalgo AJ, Gomez-Gomez E, Saez-Martinez P, Fuentes-Fayos AC, Closa A, Gonzalez-Serrano T, Martinez-Lopez A, Sanchez-Sanchez R, Lopez-Casas PP, Sarmento-Cabral A, Olmos D, Eyras E, Castano JP, Gahete MD, Luque RM. Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes. TRANSLATIONAL RESEARCH. 2023. 68-79. DOI: 10.1016/j.trsl.2022.08.016. IF: 7,8 Q1 D2
Garces MF, Buell-Acosta JD, Rodriguez-Navarro HA, Paez-Leal MC, Maldonado-Acosta LM, Peralta-Franco JJ, Burgos-Cardenas AJ, Angel-Muller E, Parada-Banos AJ, Parra-Pineda MO, Eslava-Schmalbach J, Escobar-Sarmiento CA, Lacunza E, Caminos-Cepeda SA, Castano JP, Nogueiras R, Dieguez C, Ruiz-Parra AI, Caminos JE. A longitudinal study of free leptin index in pre-eclamptic pregnancies. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2023. 1083-1094. DOI: 10.1111/jcmm.17707. IF: 5,3 Q2 D4
de Lucas MDG, Caballero I, Fernández-García JC, Domínguez-Rodríguez M, Moreno-Moreno P, Jiménez-Millán A, Botana-López M, Avilés B, Merino-Torres JF, Soto A, Tejera C, Morales C. Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study. FRONTIERS IN ENDOCRINOLOGY. 2023. DOI: 10.3389/fendo.2023.1240279. IF: 5,2 Q1 D3
Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, Bergstrom EN, Kim J, Liu XR, Blazquez-Encinas R, Giacobi C, Le Stang N, Boyault S, Cuenin C, Tabone-Eglinger S, Damiola F, Voegele C, Ardin M, Michallet MC, Soudade L, Delhomme TM, Poret A, Brevet M, Copin MC, Giusiano-Courcambeck S, Damotte D, Girard C, Hofman V, Hofman P, Mouroux J, Cohen C, Lacomme S, Mazieres J, de Montpreville VT, Perrin C, Planchard G, Rousseau N, Rouquette I, Sagan C, Scherpereel A, Thivolet F, Vignaud JM, Jean D, Ilg AGS, Olaso R, Meyer V, Boland-Auge A, Deleuze JF, Altmuller J, Nuernberg P, Ibanez-Costa A, Castano JP, Lantuejoul S, Ghantous A, Maussion C, Courtiol P, Hernandez-Vargas H, Caux C, Girard N, Lopez-Bigas N, Alexandrov LB, Galateau-Salle F, Foll M, Fernandez-Cuesta L. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. NATURE GENETICS. 2023. 607-618. DOI: 10.1038/s41588-023-01321-1. IF: 30,8 Q1 D1
Ho KKY, Kaiser UB, Chanson P, Gadelha M, Wass J, Nieman L, Little A, Aghi MK, Raetzman L, Post K, Raverot G, Borowsky AD, Erickson D, Castano JP, Laws ER, Zatelli MC, Sisco J, Esserman L, Yuen KCJ, Reincke M, Melmed S. Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification. NATURE REVIEWS ENDOCRINOLOGY. 2023. 671-678. DOI: 10.1038/s41574-023-00883-8. IF: 40,5 Q1 D1
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA, Abbracchio MP, Abraham G, Agoulnik A, Alexander W, Al-hosaini K, Bäck M, Baker JG, Barnes NM, Bathgate R, Beaulieu JM, Beck-Sickinger AG, Behrens M, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Boulay F, Bousquet C, Bräuner-Osborne H, Burnstock G, Caló G, Castaño JP, Catt KJ, Ceruti S, Chazot P, Chiang N, Chini B, Chun J, Cianciulli A, Civelli O, Clapp LH, Couture R, Cox HM, Csaba Z, Dahlgren C, Dent G, Douglas SD, Dournaud P, Eguchi S, Escher E, Filardo EJ, Fong T, Fumagalli M, Gainetdinov RR, Garelja ML, de Gasparo M, Gerard C, Gershengorn M, Gobeil F, Goodfriend TL, Goudet C, Grätz L, Gregory KJ, Gundlach AL, Hamann J, Hanson J, Hauger RL, Hay DL, Heinemann A, Herr D, Hollenberg MD, Holliday ND, Horiuchi M, Hoyer D, Hunyady L, Husain A, Ijzerman AP, Inagami T, Jacobson KA, Jensen RT, Jockers R, Jonnalagadda D, Karnik S, Kaupmann K, Kemp J, Kennedy C, Kihara Y, Kitazawa T, Kozielewicz P, Kreienkamp HJ, Kukkonen JP, Langenhan T, Larhammar D, Leach K, Lecca D, Lee JD, Leeman SE, Leprince J, Li XX, Lolait SJ, Lupp A, Macrae R, Maguire J, Malfacini D, Mazella J, Mcardle CA, Melmed S, Michel MC, Miller LJ, Mitolo V, Mouillac B, Müller CE, Murphy PM, Nahon JL, Ngo T, Norel X, Nyimanu D, O'Carroll AM, Offermanns S, Panaro MA, Parmentier M, Pertwee RG, Pin JP, Prossnitz ER, Quinn M, Ramachandran R, Ray M, Reinscheid RK, Rondard P, Rovati GE, Ruzza C, Sanger GJ, Schöneberg T, Schulte G, Schulz S, Segaloff DL, Serhan CN, Singh KD, Smith CM, Stoddart LA, Sugimoto Y, Summers R, Tan VP, Thal D, Thomas W, Timmermans PBMWM, Tirupula K, Toll L, Tulipano G, Unal H, Unger T, Valant C, Vanderheyden P, Vaudry D, Vaudry H, Vilardaga JP, Walker CS, Wang JM, Ward DT, Wester HJ, Willars GB, Williams TL, Woodruff TM, Yao CC, Ye RD. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. BRITISH JOURNAL OF PHARMACOLOGY. 2023. S23-S144. DOI: 10.1111/bph.16177. IF: 7,3 Q1 D1
Blazquez-Encinas R, Moreno-Montilla MT, Garcia-Vioque V, Gracia-Navarro F, Alors-Perez E, Pedraza-Arevalo S, Ibanez-Costa A, Castano JP. The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. 2023. 267-282. DOI: 10.1007/s11154-022-09771-4. IF: 8,2 Q1 D1
Publications 2021
Alors-Perez E, Blazquez-Encinas R, Alcala S, Viyuela-Garcia C, Pedraza-Arevalo S, Herrero-Aguayo V, Jimenez-Vacas JM, Mafficini A, Sanchez-Frias ME, Cano MT, Abollo-Jimenez F, Marin-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sanchez L, Sanchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sanchez A, Ibanez-Costa A, Sainz B, Luque RM, Castano JP. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 202 40(1):-. DOI: 10.1186/s13046-021-02153-9.
IF: 11,161 Q1 D1
Espejo-Cruz ML, Gonzalez-Rubio S, Zamora-Olaya J, Amado-Torres V, Alejandre R, Sanchez-Frias M, Ciria R, De la Mata M, Rodriguez-Peralvarez M, Ferrin G. Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 202 22(23):-. DOI: 10.3390/ijms222313073.
IF: 5,924 Q1 D3
Amado V, Gonzalez-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, Sanchez-Frias M, Garcia-Jurado G, Montero JL, Ciria R, Rodriguez-Peralvarez M, Ferrin G, De la Mata M. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. CANCERS. 2021. 13(10):-. DOI: 10.3390/cancers13102476.
IF: 6,639 Q1 D3
Jimenez-Vacas JM, Herrero-Aguayo V, Montero-Hidalgo AJ, Saez-Martinez P, Gomez-Gomez E, Leon-Gonzalez AJ, Fuentes-Fayos AC, Yubero-Serrano EM, Requena-Tapia MJ, Lopez M, Castano JP, Gahete MD, Luque RM. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2021. 106(2):E696-E710. DOI: 10.1210/clinem/dgaa877.
IF: 5,958 Q1 D2
Leon-Gonzalez AJ, Saez-Martinez P, Jimenez-Vacas JM, Herrero-Aguayo V, Montero-Hidalgo AJ, Gomez-Gomez E, Madrona A, Castano JP, Espartero JL, Gahete MD, Luque RM. Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells. ANTIOXIDANTS. 2021. 10(9):-. DOI: 10.3390/antiox10091348.
IF: 6,312 Q1 D1
Herrero-Aguayo V, Saez-Martinez P, Lopez-Canovas JL, Prados-Carmona JJ, Alcantara-Laguna MD, Lopez FL, Molina-Puerta MJ, Calanas-Continente A, Membrives A, Castilla J, Ruiz-Ravelo J, Alonso-Echague R, Yubero-Serrano EM, Castano JP, Gahete MD, Galvez-Moreno MA, Luque RM, Herrera-Martinez AD. Dysregulation of Components of the Inflammasome Machinery After Bariatric Surgery: Novel Targets for a Chronic Disease. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2021. 106(12):E4917-E4934. DOI: 10.1210/clinem/dgab586.
IF: 5,958 Q1 D2
Saeed M, Ibanez-Costa A, Patino-Trives AM, Munoz-Barrera L, Estevez EC, Aguirre MA, Lopez-Pedrera C. Expression of DDX11 and DNM1L at the 12p11 Locus Modulates Systemic Lupus Erythematosus Susceptibility. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021. 22(14):-. DOI: 10.3390/ijms22147624.
IF: 5,923 Q1 D3
Jimenez-Vacas JM, Montero-Hidalgo AJ, Gomez-Gomez E, Fuentes-Fayos AC, Ruiz-Pino F, Guler I, Camargo A, Anglada FJ, Carrasco-Valiente J, Tena-Sempere M, Sarmento-Cabral A, Castaño JP, Gahete MD, Luque RM. In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2021. 106(12):E4956-E4968. DOI: 10.1210/clinem/dgab516.
IF: 5,958 Q1 D2
Herrero-Aguayo V, Jimenez-Vacas JM, Saez-Martinez P, Gomez-Gomez E, Lopez-Canovas JL, Garrido-Sanchez L, Herrera-Martinez AD, Garcia-Bermejo L, Macias-Gonzalez M, Lopez-Miranda J, Castano JP, Gahete MD, Luque RM. Influence of Obesity in the miRNome: miR-4454, a Key Regulator of Insulin Response Via Splicing Modulation in Prostate. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2021. 106(2):E469-E484. DOI: 10.1210/clinem/dgaa580.
IF: 5,958 Q1 D2
Sanjuan-Sanjuan A, Alors-Perez E, Sanchez-Frias M, Dean-Ferrer A, Gahete MD, Heredero-Jung S, Luque RM. Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma. CANCERS. 2021. 13(19):-. DOI: 10.3390/cancers13194828.
IF: 6,639 Q1 D3
Leon-Gonzalez AJ, Jimenez-Vacas JM, Fuentes-Fayos AC, Sarmento-Cabral A, Herrera-Martinez AD, Gahete MD, Luque RM. Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers. CURRENT OPINION IN PHARMACOLOGY. 2021. 60():17-26. DOI: 1016/j.coph.2021.06.002.
IF: 5,547 Q1 D2
Lopez-Canovas JL, del Rio-Moreno M, Garcia-Fernandez H, Jimenez-Vacas JM, Moreno-Montilla MT, Sanchez-Frias ME, Amado V, Lopez FL, Fondevila MF, Ciria R, Gomez-Luque I, Briceno J, Nogueiras R, de la Mata M, Castano JP, Rodriguez-Peralvarez M, Luque RM, Gahete MD. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. CANCER LETTERS. 2021. 496():72-83. DOI: 10.1016/j.canlet.2020.10.010.
IF: 8,679 Q1 D2
Gesmundo I, Pardini B, Gargantini E, Gamba G, Birolo G, Fanciulli A, Banfi D, Congiusta N, Favaro E, Deregibus MC, Togliatto G, Zocaro G, Brizzi MF, Luque RM, Castano JP, Bocchiotti MA, Arolfo S, Bruno S, Nano R, Morino M, Piemonti L, Ong H, Matullo G, Falcon-Perez JM, Ghigo E, Camussi G, Granata R. Adipocyte-derived extracellular vesicles regulate survival and function of pancreatic beta cells. JCI INSIGHT. 2021. 6(5):-. DOI: 10.1172/jci.insight.141962. IF: 8,315 Q1 D2
Gesmundo I, Granato G, Fuentes-Fayos AC, Alvarez CV, Dieguez C, Zatelli MC, Congiusta N, Banfi D, Prencipe N, Leone S, Brunetti L, Castano JP, Luque RM, Cai RZ, Sha W, Ghigo E, Schally AV, Granata R. Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling. CANCERS. 2021. 13(16):-. DOI: 10.3390/cancers13163950. IF: 6,639 Q1 D3
Gonzalez-Borja I, Alors-Perez E, Amat I, Alonso L, Viyuela-Garcia C, Goni S, Reyes JC, Ceballos-Chavez M, Hernandez-Garcia I, Sanchez-Frias ME, Santamaria E, Razquin S, Arjona-Sanchez A, Arrazubi V, Perez-Sanz J, Vera R, Fernandez-Irigoyen J, Castano JP, Viudez A. Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma. FRONTIERS IN MEDICINE. 2021. 8():-. DOI: 10.3389/fmed.2021.720128. IF: 5,093 Q1 D2
Garces MF, Rodriguez-Navarro HA, Buell-Acosta JD, Burgos-Cardenas AJ, Franco-Vega R, Maldonado-Acosta LM, Eslava-Schmalbach J, Parada-Banos AJ, Castro-Pinzon A, Sanchez E, Angel-Muller E, Lacunza E, Castano JP, Dieguez C, Nogueiras R, Ruiz-Parra AI, Caminos JE. Maternal Serum Angiopoietin-Like 3 Levels in Healthy and Mild Preeclamptic Pregnant Women. FRONTIERS IN ENDOCRINOLOGY. 2021. 12():-. DOI: 10.3389/fendo.2021.670357. IF: 5,555 Q1 D3
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Abbracchio MP, Alexander W, Al-hosaini K, Back M, Barnes NM, Bathgate R, Beaulieu JM, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Boulay F, Bousquet C, Brauner-Osborne H, Burnstock G, Calo G, Castano JP, Catt K, Ceruti S, Chazot P, Chiang N, Chini B, Chun J, Cianciulli A, Civelli O, Clapp LH, Couture R, Csaba Z, Dahlgren C, Dent G, Singh KD, Douglas SD, Dournaud P, Eguchi S, Escher E, Filardo EJ, Fong T, Fumagalli M, Gainetdinov RR, de Gasparo M, Gerard C, Gershengorn M, Gobeil F, Goodfriend TL, Goudet C, Gregory KJ, Gundlach AL, Hamann J, Hanson J, Hauger RL, Hay DL, Heinemann A, Hollenberg MD, Holliday ND, Horiuchi M, Hoyer D, Hunyady L, Husain A, IJzerman AP, Inagami T, Jacobson KA, Jensen RT, Jockers R, Jonnalagadda D, Karnik S, Kaupmann K, Kemp J, Kennedy C, Kihara Y, Kitazawa T, Kozielewicz P, Kreienkamp HJ, Kukkonen JP, Langenhan T, Leach K, Lecca D, Lee JD, Leeman SE, Leprince J, Li XX, Williams TL, Lolait SJ, Lupp A, Macrae R, Maguire J, Mazella J, McArdle CA, Melmed S, Michel MC, Miller LJ, Mitolo V, Mouillac B, Muller CE, Murphy P, Nahon JL, Ngo T, Norel X, Nyimanu D, Ocarroll AM, Offermanns S, Panaro MA, Parmentier M, Pertwee RG, Pin JP, Prossnitz ER, Quinn M, Ramachandran R, Ray M, Reinscheid RK, Rondard P, Rovati GE, Ruzza C, Sanger GJ, Schoneberg T, Schulte G, Schulz S, Segaloff DL, Serhan CN, Stoddart LA, Sugimoto Y, Summers R, Tan VP, Thal D, Thomas W, Timmermans PMWM, Tirupula K, Tulipano G, Unal H, Unger T, Valant C, Vanderheyden P, Vaudry D, Vaudry H, Vilardaga JP, Walker CS, Wang JM, Ward DT, Wester HJ, Willars GB, Woodruff TM, Yao CC, Ye RD. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. BRITISH JOURNAL OF PHARMACOLOGY. 2021. 178():S27-S156. DOI: 10.1111/bph.15538. IF: 8,739 Q1 D1
Highlighted publications (2017-2019)
Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remón P, Solivera J, Wildemberg LE, Kasuki L, López-Fernandez JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP*, Luque R; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS.11.10.1439. DOI: 10.3390/cancers11101439. (Oncology) *Co-senior author
IF: 6,162 D2 Q1
Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler MD, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018, 70(4):763-835.(Pharmacology & pharmacy)
IF: 18.886 D1
Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP*, Luque RM. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. Mol Cancer 2017, 16(1):146. (Oncology) *Co-senior author
IF: 10.679 D1
Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Salas RO, Serrano-Blanch R, Salvatierra Á, Hofland LJ, Luque RM, Gálvez-Moreno MA, Castaño JP. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. Lung Cancer 2017, 109:128-136. (Respiratory System)
IF: 4.599 Q1
Gahete MD, Del Rio-Moreno M, Camargo A, Alcalá-Diaz JF, Alors-Pérez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martínez P, Castaño JP*, Lopez-Miranda J, Luque RM. Changes in splicing machinery components influence, precede, and early predict the development of type 2 diabetes: From the CORDIOPREV study. EBioMedicine 2018, 3964(18)30479-1. (Medicine, Research & Experimental area) *Co-senior author
IF: 6.183 D1
Ongoing projects
Alterations in the alternative splicing machinery in pancreatic cancer: Identifications of novel diagnostic, prognostic and therapeutic biomarkers. BFU2016-80360-R. PI: Justo P Castaño. Ministerio de Economía y Competitividad (MINECO). 2017-2019. 181.500€
Spliceosomic strategy to improve the diagnostic, classification and treatment of pancreatic neuroendocrine tumors. G1909. PI: Justo P Castaño. Beca GETNE 2019. 2020-2022. 60.000 €
IMIBIC Fellowship Programme for Personalised and Precision Medicine (P2Med): H2020 MSCA COFUND FP 2018. GA nr: 847468. Coordinator: Justo P Castaño. (IMIBIC). 2019-2024. EC Funding: 662.040 €. (Total cost 1.183.680 €).
Promoting STEM vocations from Biomedicine. FCT-18-13958. PI: Justo P Castaño. FECYT. 2019-2020. 20.000€.
Spliceosomic strategy in NETs for the improvement of diagnostic, classification and treatment. FERP2019. PI: Justo P Castaño. Fundación Eugenio Rodríguez Pascual 2019. 2019-2020. 7.000 €
Analysis of the in vitro combination of trastuzumab and lirilumab in breast cancer. Involvement of alternative splicing processes. PI: Cristina Morales Estévez. Sociedad Española de Oncología Médica (Beca FSEOM/BMS - Proyectos de investigación traslacional en Inmuno-Oncología 2018). 2019-2020. 40.000€.
Diagnosis and personalized postoperative prognosis of human gliomas using a new interactive approach. PI-0143-2016. PI: Juan Solivera Vela. Consejería de Salud (Junta de Andalucía). 2017-2019. 46.970,42 €
Molecular and functional characterization of bladder cancer: search of novel therapies. PI: Raúl M Luque. Eli Lilly & Company. 46.200 €. 2019-20.
Ghrelin-O-acyl-Transferase (GOAT): New Biomarker for the screening of prostate cancer. DTS18/00131. PI: Raúl M Luque. Instituto de Salud Carlos III. Proyectos de Desarrollo Tecnológico en Salud. 2018-2020. 88.550€.
Ghrelin-O-aciltransferase (GOAT): new biomarker for prostate cancer. (FIPSE Project 3188-17). PI: Raúl M Luque. 2018-2019. 30.000€.
Patents
Isoforms of the human somatostatin receptor type 5 produced by alternative processing and pairs of oligonucleotides for detection by PCR. Castaño JP, Durán Prado M, Martínez Fuentes AJ, Vázquez-Martínez R, García Navarro S, Gracia-Navarro F, Malagón MM. P200502701.
Ghrelin variant and its use. Luque RM, Castaño JP, Gahete MD, Gracia-Navarro F, Martínez-Fuentes AJ, Córdoba-Chacón J, Benito P, Kineman RD. P201030905.
Ghrelin-O-acyltransferase (GOAT) and its use. Castaño JP, Luque RM, Gahete MD, Hormaechea-Agulla D, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J, Ibáñez-Costa A, Moreno MM, Valero-Rosa J. P201531731 - PCT/ES2016/070844
Non-invasive diagnostic method for cancer. Castaño JP, Luque RM, Gahete MD, Ibáñez-Costa A, Hormaechea-Agulla D, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J.P201631606 - PCT/ES2017/070797
Peptides derived from the truncated somatostatin receptor sst5TMD4 as biomarkers and therapeutic targets in tumor pathologies. Luque RM, Castaño JP, Gahete MD, del Río-Moreno M, Alors-Pérez E. P201730702 - PCT/ES2018/070361
Method for the prediction and prognostic of the development of type 2 diabetes mellitus. Castaño JP, Luque RM, Gahete MD, López-Miranda J, Pérez-Martínez P, Delgado-Lista J, García-Ríos A, Alcalá-Díaz JF, Yubero-Serrano E, Camargo-García A, del Río-Moreno M, Alors-Pérez E, Ventura-Soto S, Reyes-Pupo O. P201831095
Method for the diagnosis, prognosis and treatment of neuroendocrine tumors. Castaño JP, Luque RM, Gahete MD, Pedraza-Arévalo S, del Río-Moreno M, Alors-Pérez E, Gálvez-Moreno MA, Herrera-Martínez A, Serrano-Blanch R. P201831039
Method for the diagnosis and prognosis of the development of prostate cancer. Castaño JP, Luque RM, Gahete MD, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J. P201930104
Method of obtaining useful data for the diagnosis, stratification and / or follow-up of patients with rheumatoid arthritis. Castaño JP, Luque RM, López-Pedrera R, Pérez-Sánchez C, Collantes-Estévez E, Ortega-Castro R, Ibáñez-Costa A, Pedraza-Arévalo S, del Río-Moreno M, Barbarroja-Puerto N, Jimenez-Gomez Y. P201930123
Method for the diagnosis and prognosis of the development of brain tumors. Luque RM, Gahete MD, Fuentes-Fayos AC, Castaño JP, Ibáñez-Costa A, Vázquez-Borrego MC, López-López F, Blanco-Acebedo C, Solivera-Vela J, Toledano-Delgado A, Gálvez-Moreno MA. P201931147.
